PPARgamma-2 and ADRB3 polymorphisms in connective tissue diseases and lipid disorders

• Published in: Clinical interventions in aging Vol. 13; pp. 463 - 472
• Main Authors: Grygiel-Górniak, Bogna, Ziółkowska-Suchanek, Iwona, Kaczmarek, Elżbieta, Mosor, Maria, Nowak, Jerzy, Puszczewicz, Mariusz
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2018; Dove Medical Press
• Subjects: Adult; Aged; Alleles; Antilipemic agents; Biochemistry; Blood lipids; C1431T; Case-Control Studies; Connective Tissue Diseases - complications; Connective Tissue Diseases - genetics; Dyslipidemias - complications; Dyslipidemias - drug therapy; Dyslipidemias - genetics; EDTA; Ezetimibe; Fenofibrate; Genes; Genetic aspects; Genetic polymorphisms; Genetic research; Genotype; Genotypes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Hypercholesterolemia; Hyperlipidemia; lipoproteins; Lipoproteins, HDL - blood; Lipoproteins, LDL - blood; Middle Aged; Original Research; Poland; Polymorphism, Genetic; PPAR gamma - genetics; Pro12Ala; Receptors, Adrenergic, beta-3 - genetics; rheumatic diseases; Statins; Triglycerides; Triglycerides - blood; Trp64Arg polymorphisms; Pro12Ala; rheumatic diseases; Trp64Arg polymorphisms; statins; lipoproteins; C1431T
• ISSN: 1178-1998; 1176-9092; 1178-1998
• DOI: 10.2147/CIA.S157186

The aim of the research genetic study was to investigate the association between variants (C1431T and Pro12Ala) of the peroxisome proliferator-activated receptor ( ) gene, Trp64Arg polymorphism of the beta-3-adrenergic receptor gene and lipid profile in Polish population including group of 103 patients with connective tissue disease (CTD) and 103 sex-and age-matched controls in context of statin use. Anthropometric and biochemical parameters were measured by routine methods, followed by genotyping (TagMan Genotyping Assays, PCR-restriction fragment length polymorphism analysis). Nearly 30% of CTD patients used statins and 10% of the control group. Although there were no differences between alleles and genotypes prevalence between CTD vs control groups, interesting lipid-gene associations were noted in this study. A higher level of triglycerides (TAG) and TAG/high-density lipoprotein (HDL) ratios was observed in CTD patients compared to controls. Similar differences were noted in CTD and control groups without statin treatment. Atherogenic markers: the atherogenic index of plasma, TAG/HDL and low-density lipoprotein/HDL ratio were low in the analyzed groups. Of the six analyzed polymorphisms, the Pro12Pro or C14131C or Trp64Trp genotypes were related to higher TAG and TAG/HDL ratios in patients with CTD; however, the highest TAG values were observed in the presence of the Trp64Trp genotype. Lipid disorders were present in both groups independent of statin treatment (mixed dyslipidemia and hypercholesterolemia were observed in the CTD and control groups, respectively). The risk of dyslipidemia increases with age. The presence of Pro12Pro, C14131C and Trp64Trp genotypes is related to higher TAG level in CTDs, and of these the Trp64Trp variant most reliably predicts hypertriglyceridemia.